Difference between revisions of "Prothrombin Complex Concentrate, human"
m (Jwarner moved page Prothrombin Complex Concentrate, Human (Kcentra) to Prothrombin Complex Concentrate, human: To accommodate multiple brand names) |
m |
||
| Line 10: | Line 10: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *4/29/2013: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm350026.htm FDA approved] "for the urgent reversal of vitamin K antagonist (VKA) anticoagulation in adults with acute major bleeding." | + | *4/29/2013: '''Kcentra''' [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm350026.htm FDA approved] "for the urgent reversal of vitamin K antagonist (VKA) anticoagulation in adults with acute major bleeding." |
==Also known as== | ==Also known as== | ||
| − | *'''Generic names:''' 4-factor prothrombin complex concentrate, PCC | + | *'''Generic names:''' 4-factor prothrombin complex concentrate, factor IX complex, PCC |
| − | *'''Brand names:''' Beriplex, Confidex, Kcentra, Octaplex | + | *'''Brand names:''' Beriplex, Confidex, Kcentra, Octaplex, Profilnine |
==References== | ==References== | ||
| Line 21: | Line 21: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| + | [[Category:Fractionated plasma products]] | ||
[[Category:Hematology medications]] | [[Category:Hematology medications]] | ||
[[Category:Hemostasis medications]] | [[Category:Hemostasis medications]] | ||
[[Category:Coagulation factors]] | [[Category:Coagulation factors]] | ||
[[Category:Drugs FDA approved in 2013]] | [[Category:Drugs FDA approved in 2013]] | ||
Revision as of 15:59, 2 December 2017
General information
Class/mechanism: Concentrate of vitamin K-dependent coagulation factors II (FII), VII (FVII), IX (FIX), X (FX), and protein C and protein S. Use of prothrombin complex concentrate can help control acute major bleeding that may result from acquired deficiency of vitamin K-dependent coagulation factors (supratherapeutic INR) in patients who are using vitamin K antagonists (VKA) such as Warfarin (Coumadin).[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Brief patient counseling information can be found on page 7 of the Prothrombin Complex Concentrate, Human (Kcentra) package insert[1]
History of changes in FDA indication
- 4/29/2013: Kcentra FDA approved "for the urgent reversal of vitamin K antagonist (VKA) anticoagulation in adults with acute major bleeding."
Also known as
- Generic names: 4-factor prothrombin complex concentrate, factor IX complex, PCC
- Brand names: Beriplex, Confidex, Kcentra, Octaplex, Profilnine